Pearl progresses with COPD metered dose inhaler; BioChemics osteoarthritis cream excels in trial;

> Pearl Therapeutics reports positive Phase IIb results from a study of glycopyrrolate, a long-acting muscarinic agonist delivered twice daily through a metered dose inhaler, for patients with moderate to severe chronic obstructive pulmonary disease. Release

> BioChemics says its Phase II study in Switzerland showed its transdermal ibuprofen-VALE cream was both effective and safe in treating osteoarthritis in the knee. Release

> A U.K. researcher says developers of drug delivery tech should focus more closely on drug carrier geometry to develop more accurate delivery systems, particularly on transport in the blood vessel. Story

> The Atlanta Business Chronicle profiled Alpharetta-based Carticept Medical, which is developing an ultrasound-guided, automatic injection device for patients with arthritis and joint pain. Story (sub. req.)

> Interarcia Therapeutics and Quintiles have inked a deal to develop Interarcia's ITCA 650, a once yearly, injection free, continuous, subcutaneous therapy to treat Type 2 diabetes. Release

> Sweden's Pharmalink will license Archimedes Pharma's TARGIT capsule drug delivery technology, which it will use as part of its treatment for the kidney disease IgA nephropathy. Release

> AngioScore, Inc. has begun enrollment patients in first-in-human trial of its drug-coated AngioSculpt scoring balloon catheter. Release